Skip to main content

Table 2 Clinical endpoints stratified by patient baseline characteristics for the overall population, in patients with squamous NSCLC, and in patients with non-squamous EGFR wild-type tumors

From: Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study

 

ORR 3/6 months (%)

DCR 3/6 months (%)

Median PFS (months)

Median OS (months)

1-year OS (%)

All patients (N = 385)

Overall

5.7/3.6

30.9/17.9

3.5

7.1

30.6

Age (years)

 65–69

4.5/1.8

25.5/12.7

3.3

7.0

26.6

 70–74

4.3/2.9

27.1/18.6

3.4

6.6

29.8

 75–79

7.4/6.4

42.6/23.4

5.0

7.9

37.2

  ≥ 80

10.8/5.4

32.4/16.2

2.9

6.0

25.6

  < 75a (n = 250)

4.4/2.4

26.4/16.0

3.3

6.8

28.3

  ≥ 75a (n = 131)

8.4/6.1

39.7/21.4

4.0

7.8

34

ECOG PS

 0

6.3/3.1

28.1/17.2

3.3

8.4

37.6

 1

6.2/3.3

31.4/16.7

3.5

6.3

29.9

  ≥ 2

4.2/5.3

33.7/23.2

3.7

7.3

29.1

Gender

 Male

5.8/2.7

31.8/16.7

3.4

6.3

25.4

 Female

5.5/5.5

29.1/20.5

4.1

8.1

41.8

Post-hoc analysis: Squamous cell histology (n = 86)

Overall

8.1/1.2

34.9/18.6

3.5

8.6

32.4

Age (years)

  < 75 (n = 55)

5.5/1.8

29.1/18.2

3.5

9.5

33.1

  ≥ 75 (n = 30)

13.3/0

43.3/16.7

3.6

7.8

29.1

ECOG PS

 0 (n = 12)

8.3/0

50.0/16.7

4.6

8.7

31.4

 1 (n = 44)

11.4/0

34.1/20.5

3.7

11.2

43.3

  ≥ 2 (n = 27)

3.7/3.7

33.3/18.5

3.5

7.3

19.2

Gender

 Male (n = 66)

6.1/1.5

33.3/16.7

3.5

8.6

28.7

 Female (n = 20)

15.0/0

40.0/25.0

4.4

9.5

44.5

Post-hoc analysis: Non-squamous EGFR wild-type (n = 91)

Overall

3.3/2.2

20.9/11.0

3.1

5.5

28.8

Age (years)

  < 75 (n = 60)

1.7/0

20.0/8.3

3.1

5.2

22.3

  ≥ 75 (n = 30)

6.7/6.7

23.3/16.7

3.2

7.9

41.7

ECOG PS

 0 (n = 18)

5.6/0

22.5/5.6

2.2

7.0

30.9

 1 (n = 50)

2.0/2.0

20.0/10.0

2.6

5.5

23.7

  ≥ 2 (n = 18)

0/5.6

22.2/22.2

4.2

6.8

39.2

Gender

 Male (n = 54)

1.9/0

18.5/5.6

2.1

4.7

16.2

 Female (n = 37)

5.4/5.4

24.3/18.9

5.0

9.3

47.9

  1. apost-hoc analysis
  2. EGFR epidermal growth factor receptor gene, NSCLC non-small-cell lung cancer, OS overall survival, PFS progression-free survival, ORR objective response rate, DCR disease control rate, ECOG PS Eastern Cooperative Oncology Group performance status